To be honest there could be several days of news next week due to the following presentations being on different days and times, probably news Monday morning and then again Tuesday morning before market opens;
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Expos...
Source: GlobeNewswire Inc.
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), today announced that five abstracts relating to the Company's lead product candidate, rigosertib, were accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, FL, which takes place December 7-10, 2019.
Oral Presentation:
1. Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Combination Therapies
Abstract: 566
Date: Monday, December 9, 2019
Presentation Time: 7:00 AM - 8:30 AM
Location: W311 EFGH (Orange County Convention Center)
Presenter: Shyamala C. Navada, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
Poster Presentations:
2. Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the INSPIRE Study (04-30)
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Abstract: 3015
Date: Sunday, December 8, 2019
Session Time: 6:00 PM – 8:00 PM
Location: Hall B (Orange County Convention Center)
Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3. The INSPIRE Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Poster III
Abstract: 4249
Date: Monday, December 9, 2019
Presentation Time: 6:00 PM - 8:00 PM
Location: Hall B (Orange County Convention Center)
Presenter: Anna Jonasova, MD, General University Hospital in Prague, 1st Internal Clinic - Clinic of Hematology, Prague, Czech Republic
4. Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: Poster III
Abstract: 4268
Session Time: 6:00 PM – 8:00 PM
Location: Hall B (Orange County Convention Center)
Presenter: Guillermo Garcia-Manero, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5. The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/ß-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome
Session Name: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster III
Abstract: 4231
Date: Monday, December 9, 2019
Session Time: 6:00 PM – 8:00 PM
Location: Hall B (Orange County Convention Center)
Presenter: Richa Rai, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
